CELL GENESYS INC CEGE (NASDAQ)

(NEW YORK) Cell Genesys Inc. said Tuesday that GVAX immunotherapy for prostate cancer, when used with ipilimumab, induces a cellular immune response that may be associated with a drop in pro...READ MORE

(NEW YORK) Wall Street applauded Takeda Pharmaceuticals' $8.8 billion cash bid for Millennium Pharmaceuticals, which will give the Japanese company access to a lucrative blood cancer dru...READ MORE

(TOKYO) Takeda Pharmaceutical Co. announced an $8.8 billion bid for U.S. biotechnology company Millennium Pharmaceuticals, an all-cash offer that would give Japan's top drug maker a k...READ MORE

(SEATTLE)Dendreon Corp. said Wednesday the Food and Drug Administration agreed to an accelerated timeline for its late-stage clinical trial of Provenge, the biotechnology company's prostate...READ MORE

Among the stock activity stories for Tuesday, Feb. 19, from AP Financial News: NEW YORK (AP) _ Shares of Bucyrus International Inc. rose Tuesday, after several analysts boosted the...READ MORE

(NEW YORK)Shares of Cell Genesys Inc. continued climbing Tuesday, following last week's report showing its vaccine candidate helped prostate cancer patients live longer in a midstage study.READ MORE

(NEW YORK)Cell Genesys Inc. shares jumped Friday after the biotechnology company reported clinical test results showing that prostate cancer patients who had an immune response to one of its...READ MORE